Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
BodySpec has opened a retail DEXA scanning location in Oakland offering roughly 12-minute body composition scans for under $60, reporting fat mass, visceral fat, lean muscle and bone density. The company positions the service against the rapid uptake of GLP-1 receptor agonists, citing evidence that 25 to 40 percent of weight lost on these drugs can be lean tissue. Muscle and bone mass are established predictors of functional independence and mortality risk, yet have historically been measured only inside clinical settings.
A Censuswide survey of 1,000 UK dieters, commissioned by nutrition brand PortionIQ, found that 29% of those using GLP-1 medications for two years or more lacked confidence in their knowledge of essential nutrients, compared with 12% of those in their first month. Only 57% of long-term users believed they were meeting their nutrient needs, against 81% of new users. With appetite suppression reducing total intake, nutrient density and protein adequacy become determinants of whether weight loss preserves or erodes lean mass and metabolic function.
Elysium has introduced Balance, a formulation combining its NAD+ precursor product Basis with S-equol and ergothioneine, positioned for perimenopausal and menopausal symptom relief alongside longer-term postmenopausal health. The company reports that an open-label pilot of Basis showed a significant increase in the estradiol-to-estrone ratio with reductions in hot flashes, disrupted sleep and bloating; a larger randomized placebo-controlled trial is planned. The estradiol-to-estrone ratio is an emerging marker of reproductive aging, making it a measurable target rather than a symptom-only endpoint.
In the REMAIN-1 pivotal cohort (N=308), a single endoscopic duodenal mucosal resurfacing procedure limited weight regain after tirzepatide discontinuation, with participants retaining roughly 80% of their drug-induced weight loss at six months versus 67% for sham. Mean regain was 5.1% versus 8.2%, and post hoc analysis indicated a dose-dependent effect, with ablation lengths of 20 cm or greater associated with 3.8% regain. The approach targets the durability problem that currently limits incretin-based weight loss as a long-term metabolic strategy.
A review of patent and development records for 25 widely used gray-market peptides found that most originated within pharmaceutical research programs rather than outside them, with many later discontinued during clinical development. The compounds circulating through compounding pharmacies and online vendors therefore carry documented histories — including the reasons their original sponsors stopped pursuing them — that are rarely referenced in consumer marketing. For anyone considering these agents as longevity interventions, that development record is the most informative available evidence on efficacy and risk.
Digbi Health has extended its genomic and gut microbiome platform to menopause care, combining hormone replacement therapy, GLP-1 prescribing, and metabolic and gastrointestinal management under a single clinical team. The rationale rests on member data showing 75% of women aged 40 to 60 already carry an obesity, cardiometabolic or gastrointestinal diagnosis. Separately released IBS outcomes from nearly 16,000 members show symptom improvement at 12 weeks, though the analysis lacks a control group and does not specify the measurement scale.
Kailera Therapeutics has completed enrollment of roughly 4,900 participants across three Phase 3 trials of ribupatide, a once-weekly injection activating both GLP-1 and GIP receptors, with topline data expected mid-2028. One trial includes an open-label semaglutide 2.4 mg comparator arm in adults with a BMI of 35 or higher, making it a direct test against the current standard rather than placebo alone. No efficacy or safety data have been released.
Analysis of the Longevity Biotech Report finds that while major drugmakers run 62% of registered industry trials on eight core aging-pathway mechanisms, essentially all recent aging-related expansion has come through acquisition rather than internal discovery. A $100 billion patent-expiry revenue gap by 2028, widening to $370 billion by 2032, alongside the long decline in R&D output per dollar spent, has made purchasing de-risked external assets the cheaper route. For the longevity field, this concentrates capital on indication-specific disease targets such as obesity and metabolic liver disease rather than aging biology itself.
Digbi Health has extended its precision telehealth platform to all 50 states, combining genetic, gut microbiome, blood biomarker and continuous glucose data into individualized metabolic care plans that may include GLP-1 medications or hormone replacement. Peer-reviewed analysis across seven self-insured employers reported a $3,012 annual reduction in medical spend per member. The model positions multi-signal personalization — rather than single-drug prescribing — as the organizing principle of metabolic care at employer scale.
A hormone-free clitoral air-pulse device has launched in UK retail pharmacy with preliminary data linking sexual stimulation to menopausal symptom relief and increased vagal tone. In a 66-woman, four-week user study, 92.9% reported improvement in at least one of more than 34 possible symptoms, a threshold met without a control group. Separate observational work in 130 menopausal women associated regular sexual activity with higher heart rate variability, consistent with greater parasympathetic regulation.
Sironax has enrolled roughly half of the target population in its global Phase 2 FORGE-LM trial of SIR4156, an orally active allosteric NAMPT activator tested alongside semaglutide in adults with obesity. The primary endpoints center on fat mass and body composition rather than weight alone, with lean mass preservation among the secondary measures. Preclinical models reported preferential fat loss and reduced muscle atrophy, though the compound remains investigational and unapproved.
Rona Therapeutics has licensed an investigational RNAi candidate silencing ALK7 (ACVR1C) to Roche, with up to $100 million upfront and near-term milestones and a further $1.06 billion tied to development and commercial milestones. ALK7 is predominantly expressed in adipose tissue, and its suppression is intended to reduce visceral and ectopic fat while preserving lean mass. The approach depends on an extrahepatic delivery platform, extending RNAi therapeutics beyond their established liver-centric territory.